Stirling Products is an Australian listed (ASX: STI) healthcare company focused on the development and commercialisation of a unique portfolio of developed products as well as an exciting pipeline of future products.

Major health issues and diseases being targeted by Stirling’s products and product candidates include: obesity, cholesterol disorders, diabetes, influenza, allergies, TB and TB/HIV co-infection.

Stirling’s animal healthcare division is focused on the manufacture and sale of its ProVale beta glucan products and the development and commercialisation of its beta agonist growth promotion agent.

The Company is headquartered in Sydney, Australia and currently has operations that are rapidly expanding either directly or through joint ventures, partnerships or distributers globally.

Stirling's four operational divisions comprise:

1. Human Healthcare Products

2. Animal Healthcare Products

3. Multi Level Marketing

4. Pharmaceutical Manufacturing (subject to completion of conditional acquisition)

We thank you for your interest in our Company and its opportunities.

Peter Boonen
Managing Director
Stirling Products Limited

Click here to see the
Melbourne Broker Presentation
(1mb PDF).